

REMARKS

Claims 20, 22, 24, 27, 35-36, 41, 46, and 52-54 have been amended.

Claims 20, 22, 24, 27, 35-36, 41, and 46 have been amended to change the multiple dependency of the originally filed claims to single dependency.

Claims 52, 53, and 54 have been amended to correct inadvertent errors in claim numbering. Specifically, claim 52 has been renumbered to claim 51. Additionally, claim 53 has been renumbered to claim 52 and renumbered to depend from claim 51. Lastly, claim 54 has been renumbered to claim 53 and renumbered to depend from claim 52.

None of these amendments add any new matter.

Applicants respectfully request that the Director consider the foregoing remarks and enter the indicated amendments prior to any fee calculations and prior to substantive examination of this application.

It is believed that there are no fees associated with this amendment; however, if Applicants are mistaken, the Director is authorized to charge any fees (or credit any overpayments) to Deposit Account Number: 50-0725, reference number VPI/03-170 US.

Respectfully submitted,

Michael C. Badia  
Reg. No. 51,424  
Agent for Applicants

Vertex Pharmaceuticals Inc.  
130 Waverly Street  
Cambridge, MA 02139-4242  
Tel.: (617)444-6467  
Fax.: (617)444-6483